Results 51 to 60 of about 1,510 (191)

A comparative study of efficacy and tolerability of bepotastine besilate (1.5%) and olopatadine hydrochloride (0.1%) eye drops in allergic conjunctivitis in a tertiary care hospital of the southern part of India

Asian Journal of Medical Sciences
Background: Allergic conjunctivitis is increasing with the rise in the levels of allergens. Drug therapy is usually needed in addition to avoidance of general allergens to treat this condition.
Sudipto Chatterjee , Vijendra R , Soumyadeep Mahapatra , Kiran Kumar L   +3 more
doaj   +1 more source

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Indian Journal of Ophthalmology, 2019
Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for ...
Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane, Manohar Babu   +4 more
doaj   +1 more source

EFFECTS OF OLOPATADINE, A NEW ANTIALLERGIC AGENT, ON HUMAN LIVER MICROSOMAL CYTOCHROME P450 ACTIVITIES

, 2020
This article is available online at http://dmd.aspetjournals.org ABSTRACT: Olopatadine, a new histamine H 1 receptor-selective antagonist, is a tricyclic drug containing an alkylamino moiety.
Keiko Inano, Eiichi Fuse, Takashi Kuwabara, Jiro Kajita, Hiroyuki Kobayashi   +4 more
core  

A Comparison of the Effects of Olopatadine and Ketotifen on Model Membranes [PDF]

Acta Ophthalmologica Scandinavica, 2000
ABSTRACT. Olopatadine is a human conjunctival mast cell stabilizer with anti‐histaminic activity. Ketotifen is an older molecule that possesses antihistaminic activity and is reported to have additional pharmacological properties. The interactions of these two compounds with model membranes (i.e., monolayers of 1‐stearoyl‐2‐oleoyl‐sn ...
H, Brockman, G, Graff, J, Spellman, J, Yanni   +3 more
openaire   +2 more sources

Comparative evaluation of Ketorolac alone and Ketorolac with Olopatadine eye drop for allergic conjunctivitis [PDF]

, 2020
Background: Seasonal allergic conjunctivitis is the most common allergic disorder of eyes. Aim: to evaluate the efficacy of 0.4% Ketorolac eye drop alone and 0.4% ketorolac with 0.1% Olopatadine eye drop in seasonal allergic conjunctivitis.Material and ...
Kumar, Rajeev, Singh, Rajiv Kumar
core   +1 more source

Permeability and biocompatibility evaluation of olopatadine hydrochloride viscous ophthalmic solutions using in vitro 3D corneal model

, 2021
Olopatadine is a selective H1-receptore antagonist that inhibits release of histamine and proinflammatory mediators [1]. The poor ocular bioavailability, as the main limitation of efficient ocular therapy, could be overcome by increasing residence ...
Dobričić, Vladimir, Račić, Anđelka, Krajišnik, Danina, Milić, Jela, Lovrić, Jasmina, Jurišić Dukovski, Bisera, Čalija, Bojan   +6 more
core   +2 more sources

Olopatadine Hydrochloride Inhibits Capsaicin-Induced Flare Response in Humans

, 2011
Capsaicin, a vanilloid, has the potential for releasing substance P (SP) from sensory nerves. Topical application of capsaicin induces a flare response in the skin.
Yuichi Yoshida, Masahisa Shindo, Osamu Yamamoto   +2 more
core   +1 more source

Formulation and Evaluation of Olopatadine Hydrochloride Opthalmic Solution

Olopatadine Hydrochloride is a selective histamine H1-receptor antagonist and mast cell stabilizer widely used in the treatment of allergic conjunctivitis.
YogeshSharma, Deepak koshti, Ramdarshan Parashar, VaibhavRajoriya, Akansha Athiya, Ajay Singh Thakur   +5 more
core   +1 more source

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis [PDF]

, 2005
Background: A nasal spray containing the antiallergy agent olopatadine hydrochloride is being developed for the treatment of seasonal allergic rhinitis (SAR).
Brubaker, M J, Potts, S L, Meltzer, E O, Barnes, J R, Wall, G M, Larsen, L V, Roland, P S, Berger, W E, Marple, B F, Bernstein, D I, Hampel, F C, Silver, L H, Ratner, P H, Finn, A F, Dimas, C   +14 more
core  

Results of Observational Study and Integration of Epinastine 0,05% in Treatment Algorythms of Patients with Seasonal Allergic Conjunctivitis

Oftalʹmologiâ
Objective. To assess tolerability and the time of onset of clinical effect of dual­-action antihistamine agents — Epinepta® (epinastine 0.05 %) and olopatadine 0.1 % in patients with seasonal allergic conjunctivitis (SAC).Subjects and methods. This was a
D. Yu. Maychuk, E. A. Drozdova, A. A. Tarkhanova, E. E. Zinych   +3 more
doaj   +1 more source